Jazz Pharmaceuticals PLC (JAZZ : NASDAQ)
Common Stock
Follow JAZZ
JAZZ
Jazz Pharmaceuticals PLC
WealthAwesomePerformance
1 Day
+0.77%
1 Week
+6.83%
1 Month
+12.37%
YTD
+41.74%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$15.63B
52W High
$266.38
52W Low
$136.56
P/E Ratio
72.05
50 Day MA
$229.39
200 Day MA
$218.09
Beta
0.37
Dividend Yield
-
Performance history
JAZZ returns since 2016
Jazz Pharmaceuticals PLC has returned +7.9% a year over the last 10 years, with 6 up years out of 9 full calendar years. Its deepest fall was −52.1% (Jun 2018 to Mar 2020).
1 year / yr
+84.3%
3 years / yr
+26.9%
5 years / yr
+12.5%
10 years / yr
+7.9%
Calendar-year returns
- 2016*−20.6%
- 2017+23.5%
- 2018−7.9%
- 2019+20.4%
- 2020+10.6%
- 2021−22.8%
- 2022+25.0%
- 2023−22.8%
- 2024+0.1%
- 2025+38.0%
- 2026*+44.4%
* Partial year (first year of data, or year to date).
$10,000 invested in JAZZ
- 1 year ago$18,427
- 5 years ago$18,004
- 10 years ago$21,471
- Best year
- 2025: +38.0%
- Worst year
- 2021: −22.8%
- All-time high in our data
- $262 on Aug 4, 2026 · now −6.2%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jan 2016 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past JAZZ? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/10/2026 | $243.55 | $246.47 | $240.77 | $245.43 | $245.43 | 576,700 |
| 11/9/2026 | $237.10 | $244.37 | $235.14 | $243.54 | $243.54 | 885,874 |
| 11/6/2026 | $226.66 | $237.76 | $225.50 | $234.76 | $234.76 | 887,600 |
| 11/5/2026 | $233.20 | $234.29 | $227.05 | $227.32 | $227.32 | 670,559 |
| 11/4/2026 | $233.23 | $234.68 | $228.45 | $234.66 | $234.66 | 896,527 |
| 11/3/2026 | $225.37 | $234.79 | $218.53 | $229.74 | $229.74 | 1,680,855 |
| 11/2/2026 | $215.84 | $218.36 | $213.81 | $214.44 | $214.44 | 1,037,067 |
| 10/30/2026 | $209.63 | $216.62 | $209.35 | $215.98 | $215.98 | 1,215,100 |
| 10/29/2026 | $207.00 | $211.32 | $205.73 | $207.83 | $207.83 | 773,557 |
| 10/28/2026 | $204.38 | $206.77 | $202.30 | $205.06 | $205.06 | 816,104 |
Analyst Price Targets
Based on 22 analysts covering JAZZ · as of Nov 9, 2026
Wall Street analysts forecast JAZZ stock price to rise 20.7% over the next 12 months.
Consensus
Strong Buy4.50 / 5.00
Avg. Target
US$296.27
+20.7% Upside
Previously US$295.50 on Nov 6, 2026
Current Price
US$245.43
Last close
Analyst Breakdown (22 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on JAZZ's historical volatility
30-Day Vol
38.6%
Annualized
90-Day Vol
31.5%
Annualized
Trend (90d)
-5.0%
Annualized drift
90d Mean
US$241.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$243.98 | US$213.57 – US$278.72 |
| 60 trading days | US$242.53 | US$200.91 – US$292.78 |
| 90 trading days | US$241.10 | US$191.45 – US$303.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Financials
- Revenue (TTM)
- $4.72B
- EBITDA
- $2.01B
- Profit Margin
- 4.36%
- ROE (TTM)
- 5.05%
- EPS (Diluted)
- 3.38
- Book Value
- 65.39
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About JAZZ.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SMX | SMX (Security Matters) Public Limited Company Class A Ordinary Shares | $19.25 | +105.88% |
| PEPG | PepGen Ltd | $4.61 | +92.89% |
| TTEC | TTEC Holdings Inc | $2.40 | +72.04% |
| NNOX | Nano X Imaging Ltd | $0.37 | +59.80% |
| TANH | Tantech Holdings Ltd | $30.56 | +58.01% |
| AACG | ATA Creativity Global | $0.89 | +52.14% |
| ESLA | Estrella Immunopharma Inc. | $0.75 | +45.40% |
| MNDO | MIND CTI Ltd | $1.26 | +44.83% |
Latest JAZZ news
Wire stories from the last 10 days. Links open the original publisher.
- Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
Yahoo Finance · 2d ago
- Jazz Pharmaceuticals (JAZZ) Stock Jumps On Q2 Earnings Turnaround
Yahoo Finance · 8d ago
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Yahoo Finance · 8d ago
- JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View
Yahoo Finance · 8d ago
- Jazz: Q3 Earnings Snapshot
Yahoo Finance · 9d ago